Cite
EP-1586 FDG PET-CT based risk-adapted radiotherapy for post-chemotherapy residual mass in advanced seminoma.
MLA
Murthy, V., et al. “EP-1586 FDG PET-CT Based Risk-Adapted Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma.” Radiotherapy & Oncology, vol. 133, Apr. 2019, p. S856. EBSCOhost, https://doi.org/10.1016/S0167-8140(19)32006-7.
APA
Murthy, V., Johnny, C., Krishnatry, R., Joshi, A., Prakash, G., Pal, M., Bakshi, G., Menon, S., Agarwal, A., Rangarajan, V., Noronha, V., & Prabhash, K. (2019). EP-1586 FDG PET-CT based risk-adapted radiotherapy for post-chemotherapy residual mass in advanced seminoma. Radiotherapy & Oncology, 133, S856. https://doi.org/10.1016/S0167-8140(19)32006-7
Chicago
Murthy, V., C. Johnny, R. Krishnatry, A. Joshi, G. Prakash, M. Pal, G. Bakshi, et al. 2019. “EP-1586 FDG PET-CT Based Risk-Adapted Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma.” Radiotherapy & Oncology 133 (April): S856. doi:10.1016/S0167-8140(19)32006-7.